<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39292392</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-190X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</Title><ISOAbbreviation>BioDrugs</ISOAbbreviation></Journal><ArticleTitle>Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40259-024-00677-y</ELocationID><Abstract><AbstractText>Chikungunya virus is an emerging mosquito-borne alphavirus that causes febrile illness and arthritic disease. Chikungunya virus is endemic in 110 countries and the World Health Organization estimates that it has caused more than 2 million cases of crippling acute and chronic arthritis globally since it re-emerged in 2005. Chikungunya virus outbreaks have occurred in Africa, Asia, Indian Ocean islands, South Pacific islands, Europe, and the Americas. Until recently, no specific countermeasures to prevent or treat chikungunya disease were available. To address this need, multiple vaccines are in human trials. These vaccines use messenger RNA-lipid nanoparticles, inactivated virus, and viral vector approaches, with a live-attenuated vaccine VLA1553 and a virus-like particle PXVX0317 in phase III testing. In November 2023, the US Food and Drug Administration (FDA) approved the VLA1553 live-attenuated vaccine, which is marketed as IXCHIQ. In June 2024, Health Canada approved IXCHIQ, and in July 2024, IXCHIQ was approved by the European Commission. On August 13, 2024, the US FDA granted priority review for PXVX0317. The European Medicine Agency is considering accelerated assessment review of PXVX0317, with potential for approval by both agencies in 2025. In this review, we summarize published data from pre-clinical and clinical trials for the IXCHIQ and PXVX0317 vaccines. We also discuss unanswered questions including potential impacts of pre-existing chikungunya virus immunity on vaccine safety and immunogenicity, whether long-term immunity can be achieved, safety in children, pregnant, and immunocompromised individuals, and vaccine efficacy in people with previous exposure to other emerging alphaviruses in addition to chikungunya virus.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Whitney C</ForeName><Initials>WC</Initials><Identifier Source="ORCID">0000-0002-5868-8085</Identifier><AffiliationInfo><Affiliation>Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Streblow</LastName><ForeName>Daniel N</ForeName><Initials>DN</Initials><Identifier Source="ORCID">0000-0002-6828-2492</Identifier><AffiliationInfo><Affiliation>Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coffey</LastName><ForeName>Lark L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-0718-5146</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis One Shields Avenue, Davis One Shields Avenue, 5327 VM3A, Davis, CA, 95616, USA. lcoffey@ucdavis.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AI125902</GrantID><Agency>Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases</Agency><Country /></Grant><Grant><GrantID>U19AI142790</GrantID><Agency>Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases</Agency><Country /></Grant><Grant><GrantID>T32GM142619</GrantID><Agency>Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>BioDrugs</MedlineTA><NlmUniqueID>9705305</NlmUniqueID><ISSNLinking>1173-8804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39292392</ArticleId><ArticleId IdType="doi">10.1007/s40259-024-00677-y</ArticleId><ArticleId IdType="pii">10.1007/s40259-024-00677-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. Chikungunya virus. Available from: https://www.who.int/health-topics/chikungunya#tab=tab_1 . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>de Lima Cavalcanti TYV, Pereira MR, de Paula SO, Franca de RFO. A review on Chikungunya virus epidemiology, pathogenesis and current vaccine development. Viruses. 2022;14:969. https://doi.org/10.3390/v14050969 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050969</ArticleId><ArticleId IdType="pubmed">35632709</ArticleId><ArticleId IdType="pmc">9147731</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. Trans Royal Soc Trop Med Hyg. 1955;49:28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0035-9203(55)90080-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Raju S, Adams LJ, Diamond MS. The many ways in which alphaviruses bind to cells. Trends Immunol. 2024;45:85–93. https://doi.org/10.1016/j.it.2023.11.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2023.11.006</ArticleId><ArticleId IdType="pubmed">38135598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn RJ. Togaviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields’ virology. 5th ed. New York: Lippincott, Williams and Wilkins; 2007. p. 1001–22.</Citation></Reference><Reference><Citation>Khan SU, Ogden NH, Fazil AA, Gachon PH, Dueymes GU, Greer AL, et al. Current and projected distributions of Aedes aegypti and Ae. albopictus in Canada and the U.S. Environ Health Perspect. 2020;128:057007. https://doi.org/10.1289/EHP5899 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/EHP5899</ArticleId><ArticleId IdType="pubmed">32441995</ArticleId><ArticleId IdType="pmc">7263460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer MU, Sinka ME, Duda KA, Mylne A, Shearer FM, Brady OJ, et al. The global compendium of Aedes aegypti and Ae. albopictus occurrence. Sci Data. 2015;2:150035. https://doi.org/10.1038/sdata.2015.35 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2015.35</ArticleId><ArticleId IdType="pubmed">26175912</ArticleId><ArticleId IdType="pmc">4493829</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol. 2010;8:491–500. https://doi.org/10.1038/nrmicro2368 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2368</ArticleId><ArticleId IdType="pubmed">20551973</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartholomeeusen K, Daniel M, LaBeaud DA, Gasque P, Peeling RW, Stephenson KE, et al. Chikungunya fever Nat Rev Dis Primers. 2023;9:17. https://doi.org/10.1038/s41572-023-00429-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-023-00429-2</ArticleId><ArticleId IdType="pubmed">37024497</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhrbier A. Rheumatic manifestations of Chikungunya: emerging concepts and interventions. Nat Rev Rheumatol. 2019;15:597–611. https://doi.org/10.1038/s41584-019-0276-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0276-9</ArticleId><ArticleId IdType="pubmed">31481759</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G, et al. French guidelines for the management of Chikungunya (acute and persistent presentations). November 2014. Med Mal Infect. 2015;45:243–63. https://doi.org/10.1016/j.medmal.2015.05.007 .</Citation></Reference><Reference><Citation>de Brito CAA, von Sohsten AKA, Leitão CCS, Brito RCCM, Valadares LDA, da Fonte CAM, et al. Pharmacologic management of pain in patients with Chikungunya: a guideline. Rev Soc Bras Med Trop. 2016;49:668–79. https://doi.org/10.1590/0037-8682-0279-2016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0037-8682-0279-2016</ArticleId><ArticleId IdType="pubmed">28001212</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb E, Michelen M, Rigby I, Dagens A, Dahmash D, Cheng V, et al. An evaluation of global Chikungunya clinical management guidelines: a systematic review. EClinicalMedicine. 2022;54: 101672. https://doi.org/10.1016/j.eclinm.2022.101672 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101672</ArticleId><ArticleId IdType="pubmed">36193172</ArticleId><ArticleId IdType="pmc">9526181</ArticleId></ArticleIdList></Reference><Reference><Citation>Vairo F, Haider N, Kock R, Ntoumi F, Ippolito G, Zumla A. Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention. Infect Dis Clin North Am. 2019;33:1003–25. https://doi.org/10.1016/j.idc.2019.08.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2019.08.006</ArticleId><ArticleId IdType="pubmed">31668189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sales GMPG, Barbosa ICP, Canejo Neta LMS, Melo PL, Leitão RA, Melo HMA. Treatment of chikungunya chronic arthritis: a systematic review. Rev Assoc Med Bras. 1992;2018(64):63–70. https://doi.org/10.1590/1806-9282.64.01.63 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1806-9282.64.01.63</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Ahmed S, Parray HA, Das S. Chikungunya and arthritis: an overview. Travel Med Infect Dis. 2021;44: 102168. https://doi.org/10.1016/j.tmaid.2021.102168 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2021.102168</ArticleId><ArticleId IdType="pubmed">34563686</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of Chikungunya and Zika viruses: a systematic review. PLoS Negl Trop Dis. 2021;15: e0009055. https://doi.org/10.1371/journal.pntd.0009055 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0009055</ArticleId><ArticleId IdType="pubmed">33661908</ArticleId><ArticleId IdType="pmc">7932082</ArticleId></ArticleIdList></Reference><Reference><Citation>Flahault A, Aumont G, Boisson V, de Lamballerile X, Favier F, Fontenille D, et al. Chikungunya, La Réunion and Mayotte, 2005–2006: an epidemic without a story? Sante Publique. 2007;19(Suppl. 3):S165–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">17929405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhabra M, Mittal V, Bhattacharya D, Rana U, Lal S. Chikungunya fever: a re-emerging viral infection. Indian J Med Microbiol. 2008;26:5–12. https://doi.org/10.4103/0255-0857.38850 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0255-0857.38850</ArticleId><ArticleId IdType="pubmed">18227590</ArticleId></ArticleIdList></Reference><Reference><Citation>Torales M, Beeson A, Grau L, Galeano M, Ojeda A, Martinez B, et al. Notes from the field: Chikungunya outbreak-Paraguay, 2022–2023. MMWR Morb Mortal Wkly Rep. 2023;72:636–8. https://doi.org/10.15585/mmwr.mm7223a5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7223a5</ArticleId><ArticleId IdType="pubmed">37289652</ArticleId><ArticleId IdType="pmc">10328456</ArticleId></ArticleIdList></Reference><Reference><Citation>Fred A, Fianu A, Béral M, Guernier V, Sissoko D, Méchain M, et al. Individual and contextual risk factors for chikungunya virus infection: the SEROCHIK cross-sectional population-based study. Epidemiol Infect. 2018;146:1056–64. https://doi.org/10.1017/S0950268818000341 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268818000341</ArticleId><ArticleId IdType="pubmed">29720285</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Sánchez JA, Ramírez-Arroyo GF. Chikungunya virus: history, geographic distribution, clinical picture, and treatment. P R Health Sci J. 2018;37:187–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">30548053</ArticleId></ArticleIdList></Reference><Reference><Citation>van Aalst M, Nelen CM, Goorhuis A, Stijnis C, Grobusch MP. Long-term sequelae of Chikungunya virus disease: a systematic review. Travel Med Infect Dis. 2017;15:8–22. https://doi.org/10.1016/j.tmaid.2017.01.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2017.01.004</ArticleId><ArticleId IdType="pubmed">28163198</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control. Chikungunya virus. Available from: https://www.cdc.gov/mosquitoes/pdfs/MosquitoBitePreventionUS_508.pdf . Accessed 29 Aug 2024.</Citation></Reference><Reference><Citation>Cherian N, Bettis A, Deol A, Kumar A, Di Fabio JL, Chaudhari A, et al. Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need. NPJ Vaccines. 2023;8:123. https://doi.org/10.1038/s41541-023-00722-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00722-x</ArticleId><ArticleId IdType="pubmed">37596253</ArticleId><ArticleId IdType="pmc">10439111</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S, Erku D, Mahalingam S, Taylor A. Immunogenicity, safety and duration of protection afforded by Chikungunya virus vaccines undergoing human clinical trials. J Gen Virol. 2024. https://doi.org/10.1099/jgv.0.001965 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001965</ArticleId><ArticleId IdType="pubmed">38421278</ArticleId></ArticleIdList></Reference><Reference><Citation>Roongaraya P, Boonyasuppayakorn S. Chikungunya vaccines: an update in 2023. Asian Pac J Allergy Immunol. 2023;41:1–11. https://doi.org/10.12932/AP-271222-1520 .</Citation><ArticleIdList><ArticleId IdType="doi">10.12932/AP-271222-1520</ArticleId><ArticleId IdType="pubmed">37029782</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Schnierle BS. Chikungunya vaccine candidates: current landscape and future prospects. Drug Des Devel Ther. 2022;16:3663–73. https://doi.org/10.2147/DDDT.S366112 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S366112</ArticleId><ArticleId IdType="pubmed">36277603</ArticleId><ArticleId IdType="pmc">9580835</ArticleId></ArticleIdList></Reference><Reference><Citation>Flandes X, Hansen CA, Palani S, Abbas K, Bennett C, Caro WP, et al. Vaccine value profile for chikungunya. Vaccine. 2023. https://doi.org/10.1016/j.vaccine.2023.07.069 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.07.069</ArticleId><ArticleId IdType="pubmed">38407992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, et al. Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol. 2012;86:13005–15. https://doi.org/10.1128/JVI.01780-12 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01780-12</ArticleId><ArticleId IdType="pubmed">23015702</ArticleId><ArticleId IdType="pmc">3497641</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon IK, Alera MT, Lago CB, Tac-An IA, Villa D, Fernandez S, et al. High rate of subclinical Chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Neglect Trop Dis. 2015;9:1–14. https://doi.org/10.1371/journal.pntd.0003764 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0003764</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine. 2013;31:3353–60. https://doi.org/10.1016/j.vaccine.2013.05.059 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.059</ArticleId><ArticleId IdType="pubmed">23727003</ArticleId><ArticleId IdType="pmc">3731778</ArticleId></ArticleIdList></Reference><Reference><Citation>Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009;200:516–23. https://doi.org/10.1086/600381 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/600381</ArticleId><ArticleId IdType="pubmed">19572805</ArticleId></ArticleIdList></Reference><Reference><Citation>Akahata W, Yang Z-Y, Andersen H, Sun S, Holdaway HA, Kong W-P, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010;16:334–8. https://doi.org/10.1038/nm.2105 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2105</ArticleId><ArticleId IdType="pubmed">20111039</ArticleId><ArticleId IdType="pmc">2834826</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallengard D, Kakoulidou M, Lulla A, Kummerer BM, Johansson DX, Mutso M, et al. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol. 2014;88:2858–66. https://doi.org/10.1128/JVI.03453-13 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03453-13</ArticleId><ArticleId IdType="pubmed">24371047</ArticleId><ArticleId IdType="pmc">3958085</ArticleId></ArticleIdList></Reference><Reference><Citation>Roques P, Ljungberg K, Kümmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, et al. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Insight. 2017;2: e83527. https://doi.org/10.1172/jci.insight.83527 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.83527</ArticleId><ArticleId IdType="pubmed">28352649</ArticleId><ArticleId IdType="pmc">5358498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wressnigg N, Hochreiter R, Zoihsl O, Fritzer A, Bézay N, Klingler A, et al. Single-shot live-attenuated Chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect Dis. 2020;20:1193–203. https://doi.org/10.1016/S1473-3099(20)30238-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30238-3</ArticleId><ArticleId IdType="pubmed">32497524</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, et al. Safety and immunogenicity of a single-shot live-attenuated Chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401:2138–47. https://doi.org/10.1016/S0140-6736(23)00641-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00641-4</ArticleId><ArticleId IdType="pubmed">37321235</ArticleId><ArticleId IdType="pmc">10314240</ArticleId></ArticleIdList></Reference><Reference><Citation>US FDA. Agnihothram S. December 8, 2023 SBRA-IXCHIQ. Report no.: 125777. Available from: https://www.fda.gov/media/174693/download . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>US FDA. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>CDC. VLA 1553 Chikungunya vaccine candidate. Available from: https://stacks.cdc.gov/view/cdc/122361 . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>Roques P, Fritzer A, Dereuddre-Bosquet N, Wressnigg N, Hochreiter R, Bossevot L, et al. Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera. JCI Insight. 2022;7: e160173. https://doi.org/10.1172/jci.insight.160173 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.160173</ArticleId><ArticleId IdType="pubmed">35700051</ArticleId><ArticleId IdType="pmc">9431671</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger V, Maurer G, Kosulin K, Hochreiter R, Larcher-Senn J, Dubischar K, et al. Combined immunogenicity evaluation for a new single-dose live-attenuated Chikungunya vaccine. J Travel Med. 2024. https://doi.org/10.1093/jtm/taae084 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taae084</ArticleId><ArticleId IdType="pubmed">38959854</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon R, Toepfer S, Sattler N, Schneider M, Narciso-Abraham M, Hadl S, et al. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study. Lancet Infect Dis. 2024; S1473-3099(24)00357–8. https://doi.org/10.1016/S1473-3099(24)00357-8 .</Citation></Reference><Reference><Citation>Weber WC, Streblow ZJ, Kreklywich CN, Denton M, Sulgey G, Streblow MM, et al. The FDA-approved chikungunya virus vaccine elicits cross-neutralizing antibody breadth extending to multiple arthritogenic alphaviruses similar to the antibody breadth following natural infection. Vaccines. 2024;12:893. https://doi.org/10.3390/vaccines12080893 .</Citation></Reference><Reference><Citation>Powers JM, Lyski ZL, Weber WC, Denton M, Streblow MM, Mayo AT, et al. Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein. PLoS Negl Trop Dis. 2023;17: e0011154. https://doi.org/10.1371/journal.pntd.0011154 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0011154</ArticleId><ArticleId IdType="pubmed">36913428</ArticleId><ArticleId IdType="pmc">10036167</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezza G, Weaver SC. Chikungunya as a paradigm for emerging viral diseases: evaluating disease impact and hurdles to vaccine development. PLoS Negl Trop Dis. 2019;13: e0006919. https://doi.org/10.1371/journal.pntd.0006919 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006919</ArticleId><ArticleId IdType="pubmed">30653504</ArticleId><ArticleId IdType="pmc">6336248</ArticleId></ArticleIdList></Reference><Reference><Citation>US FDA. FDA approves first vaccine to prevent disease caused by Chikungunya virus. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>CDC. Advisory Committee on Immunization Practices recommendations. Available from: https://www.cdc.gov/vaccines/acip/recommendations.html . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>Valneva. Valneva announces Health Canada approval of the world’s first Chikungunya vaccine, IXCHIQ<sup>®</sup>. Available from: https://valneva.com/press-release/valneva-announces-health-canada-approval-of-the-worlds-first-chikungunya-vaccine-ixchiq/ . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>Valneva. Valneva receives marketing authorization in Europe for the world’s first Chikungunya vaccine, IXCHIQ<sup>®</sup>. Available from: https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq/ . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>US FDA. Valneva: highlights of prescribing information for IXCHIQ. Available from: https://www.fda.gov/media/173758/download?attachment . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>Chang L-J, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014;384:2046–52. https://doi.org/10.1016/S0140-6736(14)61185-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61185-5</ArticleId><ArticleId IdType="pubmed">25132507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen GL, Coates EE, Plummer SH, Carter CA, Berkowitz N, Conan-Cibotti M, et al. Effect of a Chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial. JAMA. 2020;323:1369. https://doi.org/10.1001/jama.2020.2477 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2477</ArticleId><ArticleId IdType="pubmed">32286643</ArticleId><ArticleId IdType="pmc">7156994</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis. 2022;22:1343–55. https://doi.org/10.1016/S1473-3099(22)00226-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00226-2</ArticleId><ArticleId IdType="pubmed">35709798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gache HRJ, Mendy J, Muhammad S, Lauren T, Tobi L, Royalty Trendo S, et al. Positive immunogenicity and safety profile for a virus-like particle (VLP) based Chikungunya virus (CHIKV) vaccine: results from a pivotal phase III trial. Available from: https://escmid.reg.key4events.com/AbstractList.aspx?e=21&amp;preview=1&amp;aig=-1&amp;ai=19663 . Accessed 29 Aug 2024.</Citation></Reference><Reference><Citation>Goo L, Dowd KA, Lin T-Y, Mascola JR, Graham BS, Ledgerwood JE, et al. A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes. J Infect Dis. 2016;214:1487–91. https://doi.org/10.1093/infdis/jiw431 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw431</ArticleId><ArticleId IdType="pubmed">27655868</ArticleId><ArticleId IdType="pmc">5091377</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty JM, Bedell L, Mendy J, Coates EE, Chen GL, Ledgerwood JE, et al. Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals. Vaccine. 2023;41: 6146–49. https://doi.org/10.1016/j.vaccine.2023.08.086 .</Citation></Reference><Reference><Citation>Raju S, Adams LJ, Earnest JT, Warfield K, Vang L, Crowe JE, et al. A Chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Sci Transl Med. 2023;15:eade8273. https://doi.org/10.1126/scitranslmed.ade8273 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.ade8273</ArticleId><ArticleId IdType="pubmed">37196061</ArticleId><ArticleId IdType="pmc">10562830</ArticleId></ArticleIdList></Reference><Reference><Citation>US FDA. US Department of Health and Human Services. Points to consider in the characterization of cell lines used to produce biologicals (1993). Available from: https://www.fda.gov/media/76255/download . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg. 2000;62:681–5. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11304054 . Accessed 29 Aug 2024.</Citation></Reference><Reference><Citation>CEPI. CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine. Available from: https://cepi.net/cepi-awards-us234-million-valneva-late-stage-development-single-dose-chikungunya-vaccine#:~:text=With%20support%20from%20the%20European,vaccine%20(VLA1553)%20against%20Chikungunya . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>Burkett-Cadena ND, Fish D, Weaver S, Vittor AY. Everglades virus: an underrecognized disease-causing subtype of Venezuelan equine encephalitis virus endemic to Florida, USA. J Med Entomol. 2023;60:1149–64. https://doi.org/10.1093/jme/tjad070 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jme/tjad070</ArticleId><ArticleId IdType="pubmed">37862065</ArticleId></ArticleIdList></Reference><Reference><Citation>Work TH. Serological evidence of arbovirus infection in the Seminole Indians of Southern Florida. Science. 1964;145:270–2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.145.3629.270</ArticleId><ArticleId IdType="pubmed">14171866</ArticleId></ArticleIdList></Reference><Reference><Citation>Henss L, Yue C, Von Rhein C, Tschismarov R, Lewis-Ximenez LL, Dölle A, et al. Analysis of humoral immune responses in Chikungunya virus (CHIKV)-infected patients and individuals vaccinated with a candidate CHIKV vaccine. J Infect Dis. 2020;221:1713–23. https://doi.org/10.1093/infdis/jiz658 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz658</ArticleId><ArticleId IdType="pubmed">31828322</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins KA, Gregory MK, Valdez SM, Sprague TR, Encinales L, Pacheco N, et al. Neutralizing antibodies from convalescent Chikungunya virus patients can cross-neutralize Mayaro and Una viruses. Am J Trop Med Hyg. 2019;100:1541–4. https://doi.org/10.4269/ajtmh.18-0756 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.18-0756</ArticleId><ArticleId IdType="pubmed">31017081</ArticleId><ArticleId IdType="pmc">6553899</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey LL, Beeharry Y, Bordería AV, Blanc H, Vignuzzi M. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci U S A. 2011;108:16038–43. https://doi.org/10.1073/pnas.1111650108 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1111650108</ArticleId><ArticleId IdType="pubmed">21896755</ArticleId><ArticleId IdType="pmc">3179076</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemersma KK, Coffey LL. Chikungunya virus populations experience diversity-dependent attenuation and purifying intra-vector selection in Californian Aedes aegypti mosquitoes. PLoS Negl Trop Dis. 2019;13: e0007853. https://doi.org/10.1371/journal.pntd.0007853 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0007853</ArticleId><ArticleId IdType="pubmed">31751338</ArticleId><ArticleId IdType="pmc">6894883</ArticleId></ArticleIdList></Reference><Reference><Citation>Stapleford KA, Coffey LL, Lay S, Bordería AV, Duong V, Isakov O, et al. Emergence and transmission of arbovirus evolutionary intermediates with epidemic potential. Cell Host Microbe. 2014;15:706–16. https://doi.org/10.1016/j.chom.2014.05.008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2014.05.008</ArticleId><ArticleId IdType="pubmed">24922573</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey LL, Failloux AB, Weaver SC. Chikungunya virus-vector interactions. Viruses. 2014;6:4628–63. https://doi.org/10.3390/v6114628 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v6114628</ArticleId><ArticleId IdType="pubmed">25421891</ArticleId><ArticleId IdType="pmc">4246241</ArticleId></ArticleIdList></Reference><Reference><Citation>Göertz GP, Lingemann M, Geertsema C, Abma-Henkens MHC, Vogels CBF, Koenraadt CJM, et al. Conserved motifs in the hypervariable domain of chikungunya virus nsP3 required for transmission by Aedes aegypti mosquitoes. PLoS Negl Trop Dis. 2018;12: e0006958. https://doi.org/10.1371/journal.pntd.0006958 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006958</ArticleId><ArticleId IdType="pubmed">30412583</ArticleId><ArticleId IdType="pmc">6249005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ninla-Aesong P, Mitarnun W, Noipha K. Long-term persistence of Chikungunya virus-associated manifestations and anti-Chikungunya virus antibody in Southern Thailand: 5 years after an outbreak in 2008–2009. Viral Immunol. 2020;33:86–93. https://doi.org/10.1089/vim.2019.0168 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2019.0168</ArticleId><ArticleId IdType="pubmed">31976828</ArticleId></ArticleIdList></Reference><Reference><Citation>Valneva. Valneva reports further positive pivotal phase 3 data in adolescents for its single-shot Chikungunya vaccine. Available from: https://valneva.com/press-release/valneva-reports-further-positive-pivotal-phase-3-data-in-adolescents-for-its-single-shot-chikungunya-vaccine/#_ftn3 . Accessed 19 Jul 2024.</Citation></Reference><Reference><Citation>Baylis SA, Knezevic I, Almond NM. Harmonising the measurement of neutralising antibodies against chikungunya virus: a path forward for licensing of new vaccines? Lancet Microbe. 2024;S2666–5247(24):00097–101. https://doi.org/10.1016/S2666-5247(24)00097-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(24)00097-1</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>